Where most members of the telecommunications sector will soon cease to exist under the S&P and MSCI Global Industry Classification System, they will be substituted by the new communications services sector, where many telecom stocks have still performed poorly.
That may be set to change, according to Oppenheimer’s Timothy Horan. He has explained that the second half of the year will be more positive than the first for the industry, helping by improving wireless trends.
Horan believes that the communication sector has already bottomed relative to the market and that investors can expect to see stronger performance in the back half of the year, helped by largely “benign” competition on the wireless front and better average revenue per user. At this point, carriers have shifted away from the damaging price-cutting stage and are more focused on building in features aimed at squeezing higher sales from customers, he says.
Premium unlimited plans should also boost more exciting per-user revenue, in addition to ordinary price increases. Horan is anticipating that companies will continue to bundle streaming TV and video services into unlimited data plans, saying wireline broadband service is also a likely driver of sales. “The convergence of wireline and wireless is happening longer term and will lead to major consolidation,” he wrote Wednesday.
Horan’s top large-cap picks are AT&T(T) and T-Mobile US (TMUS). He notes AT&T’s dividend yield is now at 6% versus 4% for Verizon Communications (VZ), the “largest spread ever.” For T-Mobile, he expects increased market share gains and margin improvement, saying the merger with Sprint (S) will be transformational, creating a company with half the value of Verizon but nearly the same number of customers.
AT&T was down 0.1% to $33.35 in recent trading, while T-Mobile was up 0.2% to $68.50.
4 Security Penny Stocks To Watch
As Threats Arise, Security Stocks Take Center Stage In 2019
With the Federal Reserve’s meeting coming, the general market is bracing for anything. Meanwhile, penny stocks are continuing to climb at absurd rates. Trading penny stocks as of late has brought many investors fruitful profits and they look to continue this trend. Here are some security penny stocks to watch for the remainder of June 2019:
Security Penny Stock #1
Liberty Defense Holdings (SCAN.V)
Market Cap: $46.404M
Liberty Defense Holdings Ltd. (SCAN.V) is a security company looking to take the industry into the next century. Liberty’s HEXWAVE product is a 3-dimensional scanning device that can detect weapons and threats of any kind. The product can do this both with speed and discretion ensuring privacy for citizens.
Liberty signed a Memorandum of Understanding with the soccer team FC Bayern München to beta test HEXWAVE in their arena. They join an ever-growing list of places that have signed MOU’s to beta test Liberty’s product. This MOU expands its ability to comply with and test the market requirements for their product internationally.
“The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America, […] Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.”Bill Riker, CEO of Liberty
Security Penny Stock #2
Magal Security Systems (MAGS)
Market Cap: $101.371M
Magal Security Systems Ltd. (MAGS) provides security solutions both online and physical. Some services provided include identifying potential security problems, integrating new systems, and custom designs for any type of security needs.
Recently, Magal received a $5.5 million contract for its advanced perimeter intrusion detection system. The system prevents people from illegally crossing border fences and walls.
Dror Sharon, CEO of Magal, stated, “Magal is a world leader in perimeter intrusion technologies. Our growing wins of orders such as this – providing sensors for active international borders, is due to the decades of experience that we have in providing systems that have more than proven themselves in-the-field.”
Security Penny Stock #3
Rekor Systems (REKR)
Market Cap: $27.502M
Rekor Systems Inc. (REKR) is a company that has developed surveillance technology to enhance public safety, banking, and traffic management. Primarily, the company takes their advanced software, which utilizes machine learning and upgrades IP cameras to the next level. This reduces the cost when collecting highway tolls and helps manage traffic congestion.
Throughout June, Rekor Systems has been gaining recognition and application across the US. On June 3rd Rekor obtained a contract to start deploying its Mobile LBR-2 vehicle recognition systems. After this deployment on the 3rd, the LPR-2 system North Carolina law enforcement placed an order. On June 12th, Colorado highway authorities chose Rekor’s cloud system called NUMERUS to read enhance their license plate reading.
Security Penny Stock #4
BIO-key International (BKYI)
Market Cap: $18.03M
BIO-key International Inc. (BKYI) is a security technologies company that is pushing past the limits of fingerprint scanning. BIO-key provides a plethora of finger scanning products that provide security for your computer, hard drive, and the government. They have a partnership with Microsoft to develop biometric sign-in for Windows 10.
The company recently announced that a foreign defense ministry ordered more BIO-key deployment for secure access to Microsoft applications.
“We were delighted that such a capable and prestigious technology team determined that BIO-key met their security and scalability requirements and have now made follow-on investments to grow their user base. Defense Ministries are constant targets of cyber-attacks, and we are glad to help them step up authentication to the highest assurance with NIST-verified accuracy and FIPS compliance.”Jim Sullivan, SVP of BIO
Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?
Will Shares Of Palatin Technologies (PTN) Head Higher As Biotech Stocks Rally This Month?
Biotech stocks are rallying this month. Despite the “pop and drop” this sector saw earlier in the year, June has been a big month for biotechnology companies and people investing in this sector.
In fact, the iShares Trust Biotechnology ETF (IBB) has climbed by more than 8% since the start of June. This sector has been famous for producing volatile returns for investors. Furthermore, biotech penny stocks have increased that potential.
Palatin Technologies (PTN) Is A Biotech Penny Stock To Watch
One of the best performing penny stocks in the biotechnology sector this month has been Palatin Technologies Inc. (PTN). On January 2, this penny stock opened the year at $0.71 and has seen a 2019 high of $1.74. What’s more is that even though PTN stock has consolidated, it has continued to trade above $1.20.
So what’s all the excitement about? Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
The company’s main strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.
[New Research] Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
The recent excitement seems to have started in April after the company reported positive top-line results of its oral clinical study of PL-8177. The treatment is designed to address ulcerative colitis and other inflammatory bowel diseases.
“The main objective of the study was to demonstrate release of polymer-bound PL-8177 in the lower gastrointestinal tract after oral administration. Top line data showed favorable pharmacokinetics, and demonstrated PL-8177 was released in the lower gastrointestinal tract, supporting oral administration of PL-8177 using the delayed release polymer formulation.”
New Milestones From Palatine Technologies (PTN) Triggers New Highs
After hitting new highs on May 17th after posting quarterly earnings, shares of PTN stock have consolidated. Regardless, the company continues to progress. Earlier this month the company obtained orphan drug designation for PL-8177. Yes, this is the same one that I talked about above when the company received positive topline results earlier in the year.
Why is orphan drug designation important? This is a good question especially if you’re newer to biotech penny stocks or biopharmaceutical stocks, in general. In the exact words of the FDA:
“The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphanstatus”).”
Essentially it gives companies incentives above and beyond competitors. These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity. The obvious response would be favorable, which has been seen in the market over the past few trading sessions.
Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies, said in a press release, “Unlike corticosteroids, immunosuppressive agents, and biological therapies targeting specific cytokines or receptors, melanocortin receptor 1 peptides work to resolve chronic inflammations and restore normal immune function. We look forward to initiating clinical trials with PL-8177 for non-infectious uveitis, a high medical need disease with limited treatment options.”
But Here’s Why Palatin Might Be Set For More Excitement
It’s all about sex drive. You read that right. And something that hasn’t really been fully publicized is this “big FDA date.” You see on June 23rd, the application for Vyleesi (bremelanotide), a drug developed by Palatin and licensed to AMAG Pharmaceuticals (AMAG) will be up for review by the FDA as a New Drug.
Vyleesi is a novel melanocortin 4 receptor agonist under evaluation for restoring a natural sexual desire in premenopausal women with HSDD. Think of this like female Viagra. Will this become the sexiest biotech penny stock this month or will stock traders get blue balled?
Like This Article? Check Out: Small Cap Biotech Stocks See Boost From Large Cap M&A
Healthcare Penny Stocks To Watch: Driven Deliveries Inc. (DRVD), Biocept Inc. (BIOC), Cesca Therapeutics Inc. (KOOL), PhaseBio Pharmaceuticals Inc. (PHAS)
Healthcare penny stocks tend to be the largest movers among other penny stocks. This is mainly due to the amount of news they release. For example, any development in treatment becomes a news catalyst, which happens more often than other news.
Driven Deliveries Inc. (DRVD)
Driven Deliveries Inc. (DRVD) is primarily a technology company so why include it with other healthcare penny stocks? It is included because of what Driven’s technology is capable of, delivering medical and recreational marijuana. Medical marijuana legality is sweeping across the US which is only expanding the future demand for the services Driven provides.
More studies are beginning to show the positive effects of marijuana in relation to stress and pain relief. These studies make Driven’s recent announcement way more important. Driven revealed a partnership with Pure Ratios, a company selling 96-hour pain relief CBD and THC patches. This product is the only of its kind as it bypasses the digestive process and is absorbed directly into the bloodstream.
Christian Schenk, CEO of Driven, stated, “We believe that our best-in-class delivery platform coupled with Pure Ratio’s proven popular brands will provide a strong synergistic relationship between the companies. We look forward to expanding our customer base while increasing revenue and enhancing our overall brand recognition. Management has already identified several similar popular brands that it intends to add to our platform in the near future.”
Biocept Inc (BIOC)
Biocept Inc (BIOC) is a healthcare company that uses liquid biopsy technology to assess several forms of cancer for physicians. Biocept has their own liquid biopsy platform known as Target SelectorTM which can analyze tumor markers.
Recently, Biocept announced a new Target SelectorTM platform for breast cancer. It is Biocept’s second tumor-specific panel and will help target the second leading cause of death for women. In addition, Biocept’s platform allows medical personnel to evaluate patients with metastatic breast cancer which is usually very difficult. This news has brought strong volume and a 11% pre-market move.
Cesca Therapeutics Inc. (KOOL)
Cesca Therapeutics Inc. (KOOL) is a medical device healthcare company for cell-based therapeutics. Cesca is an affiliate of the BoyaLife Group which is based out of China. Cesca is using its AutoXpress platform to meet the needs regarding cardio, vascular, and immune diseases.
One of Cesca’s subsidiaries, ThermoGenesis, recently received approval for its Next-Gen AXP II System for cord blood processing. The AXP II System allows for the processing and storage of hematopoietic stem call concentrates. Also, multiple cord blood units can be processed in one centrifuge. Thanks to this approval, Cesca’s stock increased by more than 40%.
PhaseBio Pharmaceuticals Inc. (PHAS)
PhaseBio Pharmaceuticals Inc. (PHAS) is a biopharmaceutical company whose primary goal is creating and selling treatments to orphan diseases. Their primary drug is called PB2452 which reverses antiplatelet activity. PB2452 recently received positive preliminary results from Phase 2a clinical trial. These results pushed the stock from $12.19 to $14.08 on June 18th.
“If approved, PB2452 could help address these critical unmet medical needs by enhancing the safety profile of ticagrelor, which has the potential to become the only antiplatelet therapy on the market with a specific reversal agent. We look forward to reporting full results from the Phase 2a trial at an upcoming medical congress.”John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio
Search Stock Price (StockPrice.com)
Sponsored Content4 days ago
Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market
Featured3 months ago
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
Cannabis2 months ago
Two Massive Growth Industries, One Choice for Investors
Featured5 days ago
This New Technology Could Transform A Multi-Billion-Dollar Industry!
Biotechnology2 weeks ago
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
Cannabis3 weeks ago
A New Cannabis Trend That The Market Should Take Immediate Notice Of Is Here!
Featured2 months ago
Opportunity Ahead for This Healthcare Stock
Stock Market Breaking News4 weeks ago
Liberty Defense (SCAN.V) Signs MOU with the Utah Attorney General for Testing of HEXWAVE